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Amplification of the receptor tyrosine kinase ErbB2 is frequently
observed in breast cancer. Amplification of erbB2 is also associated
with multiple genomic gains and losses; however, the importance of
these associated changes is largely unknown. We demonstrate that
Brk, a cytoplasmic tyrosine kinase, is coamplified and coexpressed
with ErbB2 in human breast cancers. ErbB2 interacts with Brk and
increases its intrinsic kinase activity. Expression of Brk enhances the
ErbB2-induced activation of Ras/MAPK signaling and cyclin E/cdk2
activity to induce cell proliferation of mammary 3-dimensional acini in
culture. In a murine model of breast cancer, expression of Brk was
found to shorten the latency of ErbB2-induced tumors by promoting
cell proliferation, with no effect on protection from apoptosis. Fur-
thermore, overexpression of Brk conferred resistance to the ability of
Lapatinib, an ErbB2 kinase inhibitor, to inhibit ErbB2-induced prolif-
eration. Thus, we identified Brk as a drug target for ErbB2-positive
cancers.
amplification  lapatinib  tumorigenesis
ErbB2 belongs to the epidermal growth factor receptor (EGFR)family of receptor tyrosine kinases (1). Amplification of erbB2
occurs in approximately 25% of breast cancers and is correlated
with poor clinical outcomes (2). Although ErbB2 is not activated by
direct binding of a soluble ligand, it is activated by ligand-induced
formation of heterodimers with other EGFR family members,
namely, EGFR/ErbB1, ErbB3, and ErbB4. Overexpression of
ErbB2 can also result in ligand-independent receptor homodimer-
ization and activation (1, 3). Overexpression of neu (the murine
homologue of human erbB2) under the control of mousemammary
tumor virus (MMTV) long terminal repeat (LTR) results in
mammary tumorigenesis (4), suggesting that erbB2 can initiate
tumorigenesis in vivo.
ErbB2 is a drug target for human breast cancer. A humanized
monoclonal antibody against the extracellular domain of ErbB2,
Herceptin, in combination with chemotherapy, is used to treat
patients expressing high levels of ErbB2 (5). In patients who
respond to the treatment, Herceptin can delay mortality anywhere
between 9months and 3 years (5). However, almost 50%of patients
with tumors that contain erbB2 amplification do not respond to
Herceptin (6), and those who do respond develop resistance to the
drug, highlighting the need for better options to treat patients with
ErbB2-positive cancers. A better understanding of the ErbB2
signaling pathway can identify novel targets for combination ther-
apy that will significantly aid our ability to treat patients with
ErbB2-amplified breast cancers.
Members of theErbB2 signaling pathway can also be coamplified
with ErbB2 in breast cancer (7–10). For example, Grb7, a Src
homology domain (SH2) containing an adaptor molecule that
associates with ErbB2 and amplifies signaling by ErbB2, is a
component of the ErbB2 amplicon (10). In addition to the erbB2
amplicon, erbB2-amplified tumors also are characterized by several
gains and losses located elsewhere in the genome (7, 8). Whether
these genomic alterations contain novel members of the ErbB2
signaling pathway that are involved in initiation, progression, and
maintenance of erbB2-amplified breast tumor is poorly understood.
The nonreceptor tyrosine kinase Brk (breast tumor kinase, also
known as PTK6), located on Chr 20q13.3, was identified from a
metastatic human breast carcinoma (11, 12). Brk is overexpressed
in approximately two-thirds of breast cancers and is also overex-
pressed in cancers such as melanomas and colon and prostate
tumors. Brk expression is limited or undetectable in normal breast
epithelial cells (11), suggesting a tumor cell–specific function for this
kinase. Overexpression of Brk sensitizes human mammary epithe-
lial cell to epidermal growth factor (EGF) and heregulin stimula-
tion and increases anchorage-independent growth. Down-
regulation of Brk interferes with EGF- and Heregulin-induced cell
proliferation, suggesting that Brk contributes to signaling by mem-
bers of the EGF receptor family (12–14). Brk and ErbB2 are
simultaneously overexpressed in tissue from invasive ductal breast
carcinomas (15). Immunohistochemistry analyses demonstrated
that expression of Brk and ErbB2 and ErbB4 correlated with
metastasis-free survival (16). The coexpression of these 2 onco-
genic kinases suggested a clinically relevant link between them, but
the significance of this coexpression is not known.
Here, we demonstrate that brk is frequently coamplified with
erbB2. Brk associates with ErbB2, induces prolonged activation of
the Ras/MAPK pathway, and promotes cell proliferation. Overex-
pression of Brk cooperated with ErbB2 during murine mammary
tumorigenesis. In addition, coexpression of Brk conferred resis-
tance to the ability of ErbB2 kinase inhibitors to inhibit ErbB2-
induced cell proliferation. Thus, we identify Brk as coamplification
partner for ErbB2, and demonstrate that Brk cooperates with
ErbB2 to increase the proliferative potential of ErbB2 positive
tumors in vivo and to confer resistance to anti-ErbB2 therapies.
Results
ErbB2 and Brk Are Coamplified and Coexpressed in Human Breast
Cancers. Brk localizes to Chr 20q13.3, a region of the genome that
is frequently amplified in breast cancer (7, 8). To determine
whether brk is coamplifiedwithErbB2 in breast cancer, we analyzed
genomic changes in breast cancer, using data generated by repre-
sentational oligonucleotide microarray analyses (ROMA), an ar-
ray-based approach that uses representation to reduce genomic
complexity (17). A detailed analysis of genomic changes observed
by ROMA analysis of 202 breast cancer tumor samples of Swedish
and Norwegian origin was published elsewhere (8). To determine
whether amplification of erbB2 correlates with amplification of
genomic locus containing brk, a 2  2 contingency table was
generated for 2 categorical variables, erbB2 and brk, in 2 observation
states, amplified and nonamplified (Fig. 1A). Each entry represents
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the number of observations for a given gene (variable) in 1
observation state. Amplification of erbB2 was strongly associated
with amplification of brk, as indicated by Fisher’s exact test (P 
0.0024; odds ratio 2.8), suggesting a nonrandom association be-
tween erbB2 and brk.
To determine whether coamplification correlated with coover-
expression, we reanalyzed changes in expression of erbB2 and brk,
using a recently published cDNAmicroarray analysis dataset of 113
Norwegian breast tumors (18). The values are median-polished log
ratios of expression in tumor cells to that in a reference cell mixture.
A scatter plot of brk versus erbB2 expression for 113 Norwegian
tumors was generated, and tumors with below-median and above-
median erbB2 and brk expression are separated by vertical and
horizontal dotted lines, respectively (Fig. 2B). A linear least-squares
fit to the data are shown as a solid straight line. The slope of the fit
is 0.53 0.09 (the slope is different from 0 with a P value of 3.4
10e-8), suggesting that there is a significant correlation between
expression of erbB2 and brk.
Brk Overexpression Promotes ErbB2-Induced Cell Cycle Progression.
To investigate the effect of coexpressing Brk and ErbB2, we
expressed Brk in MCF-10A cells together with an inducible chi-
meric form of ErbB2 (herein referred to as chimeric-ErbB2 or cB2)
(19). Unlike the wild-type ErbB2 receptors, the chimeric ErbB2
cannot be activated by ligand-induced heterodimerization because
the extracellular domain is replaced with p75 nerve growth factor
receptor (20). The chimera has an FK506 binding protein (FKBP)
fused to the C terminus and can be homodimerized by using a
cell-permeable, bivalent FKBP ligand AP1510 (dimerizer) (see
Materials and Methods for details). An immortalized EGF-
dependent, nontumorigenic, human mammary epithelial cell line,
MCF-10A, was used in these studies.MCF-10A cells expressingBrk
alone (10A.Brk), ErbB2 alone (10A.cB2), or Brk with ErbB2
(10A.cB2.Brk) were generated by retroviral infections. All of the
cells used in this study were generated as pooled populations of
drug-resistant cells to avoid any clonal variations. 10A.cB2 and
10A.cB2.Brk cells expressed similar levels of the ErbB2 chimera, as
detected by anti-HA immunoblotting. 10A.Brk and 10A.cB2.Brk
cells showed comparable expression of Brk (Fig. 2A), which was
higher than the endogenous levels detected in 10A.Vec and
10A.cB2.
We have shown that dimerization of ErbB2 induces EGF-
independent proliferation of MCF-10A cells (19). We investigated
whether coexpression of Brk affected cell proliferation. Although
expression of Brk alone was not sufficient to promote EGF-
independent proliferation of MCF-10A cells, it cooperated with
ErbB2 to enhance the ability of ErbB2 to induce an increase in cell
number (Fig. 2B). In addition, the cells were analyzed by flow
cytometry to monitor changes in cell cycle. 10A.cB2.Brk cells
maintained a higher percentage of cells in the S phase at all time
points analyzed. In addition, there was a 2-fold greater percentage
of cells in the S phase in 10A.cB2.Brk cells than that observed in
10A.cB2 cells (18%vs. 9%)within the first 16 h after activation [Fig.
2C and supporting information (SI) Fig. S1], suggesting that the
cells entered the S phase faster and maintained high proliferation
rates in the presence ofBrk. Thus, Brk increasesErbB2-induced cell
proliferation by promoting rapid S phase entry.
Brk Enhances ErbB2-Induced Reinitiation of Proliferation in 3D Epi-
thelial Acini.We have demonstrated that although both ErbB1 and
ErbB2 can induce EGF-independent proliferation of MCF-10A
cells on plastic dishes, only ErbB2 reinitiates proliferation of
proliferation arrested, 3-dimensional (3D) acini structures grown in
a bed of extracellular matrix, Matrigel (19). We investigated
whether Brk cooperates with ErbB2 during reinitiation of prolif-
eration in proliferation-arrestedMCF-10A 3D acini. Both parental
ErbB2-expressing cells and the cells coexpressing ErbB2 and Brk
had low proliferation rates, as observed using Ki-67 as a prolifer-
ation cell marker, in the absence of ErbB2 activation. Stimulation
of ErbB2 induced 2- to 3-fold higher proliferation rates in 10A.cB2
Brk acini than that observed in 10A.cB2 (Fig. 2D). These results
demonstrate that overexpression of Brk enhanced the ability of
ErbB2 to reinitiate cell proliferation in 3D acini structures.
Overexpression of Brk Promotes ErbB2-Induced Activation of CyclinE/
cdk2 Complex. To determine how coexpression of Brk enhanced
ErbB2-induced proliferation, we analyzed changes in the expression
of cyclins and cell-cycle inhibitors that regulate the G1 phase of the
cell cycle. Activation of ErbB2 in serum-starved 10A.cB2.Brk cells
did not affect theErbB2-induced expression of cyclinD1 (Fig. S2A).
By contrast, expression of Brk significantly increased the ErbB2-
induced increase in Cyclin E and decrease of the cell cycle inhibitor
p27kip1 within 3 to 6 h, which was faster than that observed for
10A.cB2 cells (6–9 h) (Fig. S2B). These observations suggest that
coexpression of Brk enhances ErbB2-induced expression of cyclin
E and decreased levels of p27kip1 to promote progression through
G1 phase of the cell cycle.
The change in the levels of cyclin E and p27 suggested that Brk
may promote ErbB2-induced activation of cyclin E/Cdk2 activity.
Activation of ErbB2-induced maximal activation of Cdk2 kinase
activity within 6 h of activation of ErbB2 in cells expressing Brk,
whereas a similar increase in Cdk2 activity was not observed until
9–12 h in the absence of Brk (Fig. S2C).
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Fig. 1. CoamplificationandcooverexpressionofErbB2andBrk inhumanbreast
cancer. (A) A 2 2 contingency table was generated for 2 categorical variables,
ErbB2 and PTK6, in 2 observation states, amplified and not amplified; Each entry
represents the number of observations for a given gene (variable) in 1 observa-
tion state. Fisher’s exact demonstrated that there is a nonrandom association
between ErbB2 and PTK6 with a P value of 2  10e-3 (odds ratio, 2.8; 95%
confidence interval, 1.410561–5.601979). (B) Scatter plot of gene expression
levels of Brk versus ErbB2 expression for 113 Norwegian tumors. Vertical and
horizontal dotted lines represent median values for ErbB2 and Brk, respectively.
Linear least-squares fit to the data are shown as a solid straight line; dashed
coordinateaxis linesaredrawnthroughtheorigin.Slopeoffit is0.530.09(slope
is different from 0 with a P value of 3.4 108).
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Brk Interacts with ErbB2 and Induces Prolonged Activation of MAPK
Pathway. To gain insight into how ErbB2 and Brk cooperate to
promote cell cycle progression, we investigated whether Brk is a
novel component of the ErbB2 signal transduction pathway. Acti-
vation of ErbB2 resulted in an association between ErbB2 and Brk
as determined by coimmunoprecipitation analysis (Fig. 3 A and B).
In addition, ErbB2 and Brk interact with each other in an ErbB2
overexpressing breast cancer-derived cell line, T47D (Fig. 3C). To
determine whether ErbB2 increased the intrinsic kinase activity of
Brk, anti-Brk immunoprecipitates were subjected to in vitro auto-
phosphorylation assays. Although Brk immunoprecipitated from
cell lysates that do not express ErbB2 did not show any significant
change in response to stimulation with dimerizer, activation of
ErbB2-induced the intrinsic kinase activity of Brk (Fig. 3D Top).
The modest increase in the kinase activity in 10.Brk cells at 60 min
is due to higher level of total Brk present in the immunoprecipitate
(Fig. 3D Bottom). Interestingly the highest change in ErbB2-
induced increase in Brk activity was observed at 30 min and
returned to basal levels by 60 min, suggesting that there is temporal
regulation of Brk activity by ErbB2. We have demonstrated that
activation of Brk is associated with phosphorylation of Tyr-342
within its kinase domain (21). We generated an antibody that can
recognize phosphorylated Tyr-342 to serve as an independent assay
to monitor changes in Brk activation. Dimerization of ErbB2
induced a significant increase in phosphorylation of Tyr-342 that
was not observed in Brk immunoprecipitates from lysates derived
from cells that do not express ErbB2 (Fig. 3D). As observed in the
in vitro kinase assay, the highest levels of phospho-Brk were
observed 30 min after ErbB2 activation and retuned to basal levels
by 60 min. Taken together, these analyses demonstrate that ErbB2
directly recruits Brk and transiently activates the intrinsic kinase
activity of Brk.
Two key events downstream of ErbB2 are activation of the
Ras/MAPK and PI3K/Akt pathways (1). We monitored changes in
phosphorylation of Mek, Erk, and Akt to determine whether
coexpression of Brk affects ErbB2-induced downstream signaling.
ErbB2 induced a maximal increase in phosphorylation of Mek and
Erk within 15 min of dimerization both in parental and Brk
overexpressing cells (Fig. 3E). In the absence of Brk coexpression,
phosphorylation of Erk began to decrease by 30 min and reached
basal levels by 60–120 min. In contrast, in cells coexpressing Brk,
ErbB2-induced phosphorylation of Erk was sustained throughout
the 120 min (Fig. 3E). Coexpression of Brk did not have an effect
on ErbB2-induced changes in phosphorylation of Akt (Fig. 3E),
suggesting that among the signaling pathways downstream of
ErbB2, Brk selectively enhances the Ras/MAPK pathways but not
the PI3K/Akt pathway. The prolonged activation was not to due an
increase in autophosphorylation of ErbB2, because we did not
observe any difference in the levels of tyrosine phosphorylated
ErbB2 in cells expressing Brk (Fig. 3E). Thus, we demonstrate that
Brk is a novel component of the ErbB2 signaling pathway that
prolongs activation of Ras/MAPK.
Brk Kinase Activity Is Required for ErbB2-Induced Proliferation and
Decreases Lapatinib Efficacy. To determine whether Brk is required
for ErbB2-induced cell proliferation, we expressed a Brk mutant
(K219M) that lacks intrinsic kinase activity and that will function as
a dominant negative to interfere with the ErbB2-Brk signaling axis.
Expression of the kinase-dead version of Brk (kd.Brk) significantly
inhibited ErbB2-induced BrdU incorporation (Fig. 4A), demon-
strating that the Brk kinase plays a critical role during ErbB2-
induced cell proliferation in mammary epithelial cells.
Molecules that cooperate with ErbB2 to promote proliferation
are likely to have an impact on anti-ErbB2 therapeutics. To
determine whether coexpression of Brk affects the ability of an
ErbB2 kinase inhibitor to inhibit proliferation, we investigated the
ability of ErbB2 to induce proliferation in the presence of increasing
concentrations of Lapatinib, an ATP-competitive small- molecule
inhibitor of ErbB2 and EGFR. Coexpression of Brk significantly
increased the amount of Lapatinib required to inhibit ErbB-
induced proliferation (Fig. 4B) demonstrating that Brk decreases
the efficacy of Lapatinib action in ErbB2-responsive mammary
epithelial cells.
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Fig. 2. Brk enhances ErbB2-
induced proliferation of
MCF-10A cells. (A) MCF-10A
cell populations transfected
with empty vector pLPCX
(10A.vec), or vectors express-
ing Brk (10A.Brk), chimeric
ErbB2 (10A.cB2), or both Brk
and chimeric ErbB2
(10A.cB2.Brk) were gener-
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stimulated with carrier
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in cell numbers (B) or in the
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(C) were determined. Data
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dependent experiments. (D)
10A.cB2 and 10A.cB2Brk cells
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Brk Synergizes with ErbB2 in Promoting Murine Mammary Tumori-
genesis. The in vivo significance of the ErbB2-Brk pathway was
determined by using an orthotopic transplantation-based mam-
mary tumorigenesis model with an immortalized pluripotent mam-
mary epithelial cell line, Comma-1Dgeo (CD). When trans-
planted into epithelium-free mammary fat pads of syngenic
BALB/c mice, parental CD cells form hyperplastic mammary
ductal outgrowths (22) and spontaneously form tumors by 4
months. To determine the effect of coexpressing ErbB2 and Brk,
Comma-1D cells stably overexpressing ErbB2 alone or both Brk
and ErbB2 (referred as CD.B2 and CD.B2.Brk, respectively) were
generated (Fig. 4C). The engineered cells were injected into the
cleared fat pads of 3-week-old female BALB/c mice, and tumor
occurrence was monitored over time. Both CD.B2- and
CD.B2.Brk-transplanted mice developed mammary tumors (Fig.
4D). CD.B2.Brk-transplanted mice started to develop mammary
tumors an average of 73 days after transplantation, compared with
the average latency of 95 days inCD.B2-transplantedmice (Fig. 4E)
(P 0.01). Comma-1D cells expressing Brk alone or empty vector
could also induce tumors in cleared fat pads, with latencies of 98 and
125 days on average, respectively.
Both CD.B2 and CD.B2.Brk cells gave rise to tumors with
epithelial properties, as monitored by expression of E-cadherin
(Fig. 4F). To determine whether the shorter latency was due to
changes in rates of cell proliferation or to a decrease in cell
apoptosis or both, tumor tissues were analyzed by using a prolif-
eration marker Ki-67, or for the presence of terminal deoxynucleo-
tidyl transferase biotin-dUTP nick end labeling (TUNEL)-positive
cells. Consistent with the in vitro cell cycle data, CD.B2.Brk tumors
showed increased proliferation, as reflected by a higher percentage
of Ki-67-positive cells compared with CD.B2 tumors (78% cells in
CD.B2.Brk tumors and 45% cells in CD.B2 tumors) (Fig. 4F).
Furthermore, coexpression of Brk increased the level of phosphor-
ylated-MEK in CD.B2.Brk tumors (32% positive cells) compared
with CD.B2 tumors (17% positive cells) (Fig. 4F), suggesting that
the ErbB2-Brk coexpression enhances signaling to the Ras/MAPK
pathway both in culture and in vivo. There was no significant
difference in the rates of cell apoptosis (6% for CD.B2 and 8% for
CD.B2.Brk) as monitored by TUNEL labeling (Fig. 4F), suggesting
that the ErbB2-Brk pathway promotes mammary tumorigenesis by
regulating proliferation and not by protecting cells from apoptosis.
Discussion
We have identified Brk as a novel component of the ErbB2
signaling pathway that is coamplified and cooverexpressed with
ErbB2 in human breast cancer.
We demonstrate that coexpression of Brk and ErbB2 promotes
proliferation by inducing prolonged activation of the Ras/MAPK
pathway. The relationship between prolonged activation of the
Ras/MAPK pathway and cell cycle is consistent with several
reports, using fibroblasts in which extended activation of Ras/
MAPK is required for stimulation of cell cycle progression (23, 24).
Our results are consistent with previous reports in which cooper-
ation between growth factor and integrin signaling is required for
induction of CyclinE/Cdk2 but not cyclin D1 in epithelial cells (25).
Overexpression of cyclin E is observed in ER-negative tumors and
is associated with cancer relapse and patient death (26–28). The
mechanisms by which cyclin E levels increase in breast tumors are
poorly understood. Our observation provides an insight into this
process. It identifies activation of Brk as an inducer of cyclinE/Cdk2
activity.
Brk contains a modular arrangement of domains that resembles
the arrangement in Src-family kinases (SH3-SH2-catalytic). We
have showed that, like Src-family kinases, Brk is also regulated by
intramolecular interactions involving the SH3 and SH2 domains
(21). Mutation of the C-terminal tyrosine 447, which is analogous
to the regulatory Y527 of Src, increased the activity of Brk toward
cellular substrates and synthetic peptides (21, 29). Disruption of the
SH2- and SH3-mediated interactions promotes autophosphoryla-
tion at Ty342 (in the kinase activation loop) and enhances kinase
activity toward exogenous substrates. Activation of ErbB2 induced
an increase phosphorylation of Tyr-342 and activation of the
intrinsic kinase activity of Brk. Consistent with our findings, Brk is
potentially the target of other receptor tyrosine kinases implicated
in breast cancer. For example, Brk interacts with EGFR and
promotes activation of PI 3K/Akt pathway (30). In addition,
stimulation with insulin-like growth factor-1 (IGF-1) activates Brk
(31). Both EGFR and IGF-1R are activated in human breast
cancer. Thus, in addition to the ErbB2 pathway, activation of Brk
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may play a critical role in multiple signaling pathways implicated in
breast cancer.
Brk expression is lowor undetectable in normalmammary tissues
or in benign lesions. However, approximately two-thirds of the
breast tumors that were examined expressed significant levels of
Brk (11). Current evidence suggests that Brk has a direct role in
promoting carcinoma cell proliferation (12–14). Our results dem-
onstrate the Brk is required for ErbB2-induced cell proliferation in
breast epithelial cells. Furthermore, we show that Brk decreases the
efficacy of Lapatinib, an ErbB2 kinase inhibitor. Together these
results suggest that expression of Brk contributes to the develop-
ment of ErbB2-postive breast cancer and the acquisition of resis-
tance to anti-ErbB2 therapeutic strategies. Brk is potentially an
attractive therapeutic target because Brk does not promote prolif-
eration in normal adult cells (its expression in normal tissues is
restricted to nonproliferative cells in the gastrointestinal tract and
skin) (12, 29). This relatively restricted role in normal physiology
suggests that targeting Brk might produce fewer unwanted side
effects than other oncogenic kinases (12). Along these lines,
targeted disruption of Sik, the murine homolog of Brk, resulted in
mice that were viable and fertile (36). Thus, Brk inhibitors could
potentially be used in combination therapy with ErbB2 inhibitors to
treat patients with advanced ErbB2-positive breast cancer, and in
patients who develop resistance to ErbB2 inhibitors.
Materials and Methods
Materials. MCF-10A cells were obtained from ATCC, MCF-10A cells expressing
ErbB2 chimera (10A.cB2) were described in ref. 19. Culturing of MCF-10A-based
cell lines and 3D culture assays were performed as outlined in ref. 32. Comma-
1Dgeo cells were a kind gift from Daniel Medina and were cultured in DMEM/
F12 as described in ref. 22. The dimerizing compound, AP1510, was generously
provided by ARIAD Pharmaceuticals (www.ariad.com). Antibodies against p27,
E-cadherin, ERK2 and MEK1, and phosphotyrosine were obtained from BD Trans-
duction Laboratories. Anti-phospho-ERK1/2 was from Biosource. Anti-phospho-
MEK1/2 and anti-phospho-Akt were from Cell Signaling. Antibodies against
cyclin D1, cyclin E, Brk, and cdk2 were from Santa Cruz Biotechnology. Anti-
phospho-Brk (Y342) was from Upstate Biotech. Anti-HA was from Covance.
Anti-ErbB2 and anti-phospho-ErbB2 (Y1248) were from NeoMarkers. Anti--
actin was from Sigma. Anti-BrdU was from Roche. Anti-Ki-67 was from Onco-
gene. Anti-mouse or anti-rabbit antibody conjugated with Alexa Fluor dyes were
from Molecular Probes. Goat F(ab)2 anti-mouse IgG (HL) was from Caltag
Laboratories. Anti-fade Prolong reagent was from Molecular Probes. BrdU was
from Sigma. Histone H1 were purchased from Roche. [-32P] ATP was from
Amersham Biosciences. Trilogy solution was from Cell Marque. TUNEL assay kit
was from Molecular Probes.
Fig. 4. Brk enhances ErbB2-induced mammary
tumorigenesis in mice. (A) 10A.cB2.Brk (Brk) or
10A.cB2.kd-Brk (kd-Brk) cells were starved for 36 h
and stimulated with AP1510 (). BrdU was added
for the last 4.0 hours of stimulation. The amount of
BrdU incorporation was quantitated as outlined in
Materials and Methods. (B) 10A.cB2 or 10A.cB2.Brk
cellswere starvedandstimulatedwithAP1510 in the
presence of increasing concentrations of Lapatinib.
The amount of BrdU incorporation was determined
as outlined above. (C) Comma-1D cells expressing
full-length ErbB2 (CD.B2) or full-length ErbB2 and
Brk (CD.B2.Brk) were generated. (D) CD.B2 or
CD.B2Brk cells were transplanted into epithelium-
freemammaryfatpadsof syngenicBALB/cmice,and
mammary tumorigenesis was monitored. Image
shows representative animal transplanted with
CD.B2 and CD.B2.Brk in contralateral sides. (E) Tu-
mor growth was monitored over time starting from
8 weeks post-transplantation. Kaplan–Meier curve
shows incidence of mammary tumor in mice trans-
planted with different cell types. Statistical signifi-
cance for the difference between CD.Brk and
CD.B2.Brk was determined by the log-rank test (*,
P 0.05) (F) Tumors from CD.B2 or CD.B2.Brk trans-
plantationwerefixedandsectionedtoperformH&E
staining; expression of ki-67 and E-cadherin, and the
presence of phosphorylated Mek (p-Mek) was mon-
itored by immunohistochemistry. The presence of
apoptotic nuclei was monitored by TUNEL.
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BrdU Incorporation. Serum- and growth factor-starved cells were treated with
AP1510 and BrdU was added to medium at final concentration of 110 mM at 4 h
before fixation. Cells were fixed with methanol at room temperature for 5 min.
Cells were then washed with PBS:Glycine (1 M glycine in PBS) and digested with
EcoR1 and Exonuclease III at 37°C for 30 min sequentially. Cells were blocked for
60min in10%goat seruminwashingbufferandstainedwithanti-BrdUantibody
for60minfollowedbyincubationofAlexaFluor-conjugatedsecondaryantibody.
DNA was stained with DAPI.
Proliferation assays were also done by using the BrdU Cell Proliferation kit
from Chemicon. All assays were performed in triplicate. MCF10A cells expressing
WT Brk or K219M Brk, or for other experiments, cells expressing ErbB2 chimera
alone or in combination with WT BRK, were plated at a density of 2104 cells per
well of a 96-well culture dish. The cells were starved for 36 h and treated with 1
mM AP1510 or ethanol as control. For detecting resistance to Lapatinib, 1 mM
AP1510 with varying concentrations of Lapatinib (0–500 nM) was added. BrdU
was added 12 h after AP1510 stimulation for 4 h. The cells were then fixed and
incubated with anti-BrdU antibody, and washed as per the manufacturer’s in-
structions. The absorbance in the wells was read at 450 nm wavelength. The
absorbance values were normalized against the control wells (DMSO). Averaged
data from multiple experiments were plotted along with the SEM.
Cdk2KinaseActivity Assay. The kinase assay was performed as outlined in ref. 33.
The PVDF membrane was exposed to film and then incubated with anti-Cdk2
antibodies by after Western blot analysis to determine the total amount of Cdk2
in the immunoprecipitates.
Assays for BRK Activation. Immediately following AP1510 treatment, the cells
werewashedoncewith ice-coldPBScontaining1mMsodiumorthovanadateand
scrapedinto500lof lysisbuffer (25mMTris-ClpH8.5,1mMEDTA,100mMNaCl,
1% Nonidet-P40, 0.1 mM sodium orthovanadate, 0.05 g/m each aprotinin and
leupeptin, and 1 mM PMSF). One-half of the anti-BRK (Santa Cruz Biotechnology)
immunoprecipitate was incubated in a kinase assay mixture containing 100 mM
Tris-Cl pH 7.5, 10 mM MgCl2, 1 mg/ml BSA, 0.1 mM sodium orthovanadate, 500
M substrate peptide, and 500 M unlabeled ATP with 0.13 M (10 Ci) radio-
labeled ATP. The other half of the immunoprecipitate was used for immunoblot-
ting with anti-phospho BRK antibody to detect phosphorylation of the BRK
activation loop tyrosine (Y342).
3D Culture and Immunofluorescence. The 3D culture of MCF-10A cells on base-
ment membrane and immunofluorescence analysis were carried out as described
(19, 32, 34).
Fat Pad Transplantation. Fat pad transplantation in BALB/c mouse was per-
formed as described in ref. 22. Briefly, Comma-1D cells stably expressing vector,
Brk, ErbB2, or ErbB2 and Brk were trypsinized and collected in serum-containing
medium. Cells were spin down and resuspended in serum-free DMEM/F12 me-
dium. A 10-l quantity of cell resuspension containing 100,000 cells was injected
into the epithelium-cleared mammary fat pad of 3-week-old, female BALB/c mice
(Jackson Laboratories). Tumor growth was monitored every week after 8 weeks
oftransplantation.AllanimalprotocolswereapprovedbytheColdSpringHarbor
Laboratory IACUC.
Hematoxylin and Eosin Stain and Immunohistochemistry. The mammary tumors
isolated from mice that had undergone transplantation were fixed in 4% for-
malin, embedded in paraffin, and sectioned. Hematoxylin and eosin staining for
histological evaluation was performed in the Animal Shared Resource at Cold
Spring Harbor Laboratory. For immunohistochemical analysis, the tissue section
was deparaffinized in Xylene, antigen retrieval in Trilogy solution, using a pres-
sure cooker, blocking in 10% goat serum in PBS-T (0.01% Triton X-100 in PBS),
primaryantibodies incubation,andAlexaFluor-conjugatedsecondaryantibodies
incubation. The nuclei were stained with DAPI. The slides were mounted with
antifade prolong reagent.
Analysis of Human Breast Cancer Samples. A complete description of the patient
samples, ROMA, and statistical analysis have been described elsewhere (8). To
determine whether overexpression of ErbB2 correlated with overexpression of
Brk, we analyzed changes in gene expression of 113 Norwegian tumors, using a
published dataset generated by cDNA microarray analysis (18); a subset of those
tumors were also analyzed for DNA copy number changes, using ROMA. The
values are median-polished log ratios of expression in tumor cells to that in a
reference cell mixture.
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